Table 3.
Summary of main laboratory results.
| Total (n=100) |
Survivor (n=77) |
Non-survivor (n=23) |
P | |
|---|---|---|---|---|
| Lymphocyte count (10E3/μL), median, IQR | 0.9 (0.7-1.3) | 1 (0.7-1.4) | 0.7 (0.5-1.1) | <0.01 |
| <1.3 | 55/77 (71.4%) | 36/55 (65.5) | 19/22 (86.4) | 0.094 |
| <0.8 | 31/77 (40.3%) | 18/55 (32.7) | 13/22 (59.1) | 0.042 |
| Platelets (10E3/μL), median, IQR | 155 (136-205.2) | 159 (136-239.5) | 155 (100-188) | 0.189 |
| <140 | 24/78 (30.8%) | 15/56 (26.8) | 9/22 (40.9) | 0.278 |
| ≥140 | 54/78 (69.2%) | 41/56 (73.2) | 13/22 (59.1) | |
| C-reactive protein (mg/dL), median, IQR | 4 (2-9.6) | 2.7 (1.5-6.5) | 6.3 (3.3-17.6) | <0.01 |
| Procalcitonin (μg/L), median, IQR | 0.05 (0.03-0.13) | 0.04 (0.03-0.08) | 0.12 (0.1-0.5) | <0.01 |
| <0.1 | 53/79 (67.1%) | 44/56 (78.6) | 9/23 (39.1) | <0.01 |
| ≥0.1 a <0.25 | 12/79 (15.2%) | 5/56 (8.9) | 7/23 (30.4) | 0.022 |
| ≥0.25 a <0.5 | 6/79 (7.6%) | 4/56 (7.1) | 2/23 (8.7) | 1.0 |
| ≥0.5 | 8/79 (10.1%) | 3/56 (5.4) | 5/23 (21.7) | 0.042 |
| D-dimer (ng/mL), median, IQR | 284 (219-794) | 274 (208-680.5) | 2010 (565-) | 0.154 |
| ALT (U/L), median, IQR | 24 (15-37) | 24.5 (15-38.7) | 24 (17-34) | 0.754 |
| ≤41 | 64/79 (81.0%) | 44/56 (78.6) | 20/23 (87.0) | 0.533 |
| >41 | 15/79 (19.0%) | 12/56 (21.4) | 3/23 (13.0) | |
| LDH (U/L), median, IQR | 256 (192.5-345.7) | 226 (191-297) | 316 (224-434) | 0.047 |
| ≤250 | 32/66 (48.5%) | 28/49 (57.1) | 4/17 (23.5) | 0.024 |
| 250-500 | 28/66 (42.4%) | 17/49 (34.7) | 11/17 (64.7) | 0.046 |
| >500 | 6/66 (9.1%) | 4/49 (8.2) | 2/17 (11.8) | 1.0 |
| IL-6 (pg/mL), median, IQR | 166.3 (61.4-) | 166.3 (61.4-) | - | - |
| Blood urea nitrogen, (mg/dL), median, IQR | 31 (19-79) | 21 (17-31) | 106 (61.7-205.7) | <0.01 |
| Ferritin (μg/L), median, IQR | 598 (267-1048.5) | 494 (153-681) | 2922 (676-) | 0.222 |
| NTproBNP (ng/L), median, IQR | 1036 (274-3981) | 465 (74-2500.5) | 1520.5 (588.2-5900) | 0.012 |